Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Steroid Biochem Mol Biol. 2005 Oct;97(1-2):165-72. Epub 2005 Aug 1.

Responsiveness of human retinoblastoma and neuroblastoma models to a non-calcemic 19-nor Vitamin D analog.

Author information

  • 1Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, F4/344 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792-3284, USA. dalbert@wisc.edu

Abstract

OBJECTIVES:

To investigate the effectiveness of 2-methylene-19-nor-(20S)-1alpha-hydroxybishomopregnacalciferol (2MbisP) in inhibiting the growth of retinoblastoma (RB) and neuroblastoma (NB).

METHODS:

For the RB study, the xenograft athymic mouse/human retinoblastoma cell (Y-79) model and the transgenic beta-luteinizing hormone-large T antigen (LHbeta-Tag) mice were systemically treated with 2MbisP or vehicle for 5 weeks. For the NB study, the xenograft athymic mouse/human neuroblastoma cell (SK-N-AS) model was treated with 2MbisP or vehicle for 5 weeks. Tumor size and toxicity were assessed.

RESULTS:

In the xenograft models of RB and NB, 2MbisP caused statistically significant inhibition of tumor growth. Tumor growth inhibition was also observed in the transgenic RB mice, but did not achieve statistical significance. In all the groups, no biologically significant toxic effects were observed using the following variables: serum calcium levels, degree of kidney calcification, changes in body weight or survival.

CONCLUSIONS:

In athymic mice, 2MbisP was effective in inhibiting RB and NB growth compared with controls. A lesser effect was seen in the transgenic RB model. 2MbisP did not cause hypercalcemia or a significant increase in mortality.

CLINICAL RELEVANCE:

2MbisP should be considered for use in clinical trials of RB and NB.

PMID:
16055326
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk